TY - JOUR
T1 - The Risk of subsequent malignancies in women with uterine papillary serous or clear cell endometrial cancers
AU - Hinshaw, Hilary D.
AU - Smith, Ashlee
AU - Rungruang, Bunja
AU - Kelley, Joseph L.
AU - Beriwal, Sushil
AU - Krivak, Thomas C.
AU - Sukumvanich, Paniti
AU - Olawaiye, Alexander B.
PY - 2013/7/1
Y1 - 2013/7/1
N2 - Objective: Type II endometrial cancers include uterine papillary serous carcinoma (UPSC) and clear cell endometrial cancer (CC). Given their relative rarity, aggressive nature, and poor prognosis, little is known about the risk of subsequent malignancies at other sites. Our objective was to determine if women with UPSC or CC are at increased risk of subsequent malignancies. Methods: Women diagnosed with UPSC or CC were identified from the SEER (Surveillance Epidemiology and End Results) Program from 1973 to 2005. Cases with a second gynecologic malignancy were excluded. Using SEER * Stat software, standardized incidence ratios (SIRs) of subsequent malignancies were calculated. Results: A total of 8045 and 1740 patientswere diagnosed with UPSC and CC, respectively. Four hundred sixty-one (5.7%) of the UPSC cases were diagnosed with at least 1 additional nongynecologic malignancy. Significant associations were found with the following malignancies: the renal pelvis, soft-tissue sarcomas, acutemyeloid leukemia, the bladder, and colon. Seventy-eight CC cases (4.5%) were diagnosed with at least 1 additional malignancy. In comparison with the baseline population risk, there was no statistically significant increased risk of any subsequent malignancy with a primary diagnosis of CC. Conclusions: This is the first large population-based analysis of second primary malignancies after type II endometrial cancers. Uterine papillary serous carcinoma is associated with increased risks of certain subsequent malignancies, and providers should be aware of these when following up patients with this diagnosis, especially those with stage I disease. In contrast, no such associations were found with CC in this cohort.
AB - Objective: Type II endometrial cancers include uterine papillary serous carcinoma (UPSC) and clear cell endometrial cancer (CC). Given their relative rarity, aggressive nature, and poor prognosis, little is known about the risk of subsequent malignancies at other sites. Our objective was to determine if women with UPSC or CC are at increased risk of subsequent malignancies. Methods: Women diagnosed with UPSC or CC were identified from the SEER (Surveillance Epidemiology and End Results) Program from 1973 to 2005. Cases with a second gynecologic malignancy were excluded. Using SEER * Stat software, standardized incidence ratios (SIRs) of subsequent malignancies were calculated. Results: A total of 8045 and 1740 patientswere diagnosed with UPSC and CC, respectively. Four hundred sixty-one (5.7%) of the UPSC cases were diagnosed with at least 1 additional nongynecologic malignancy. Significant associations were found with the following malignancies: the renal pelvis, soft-tissue sarcomas, acutemyeloid leukemia, the bladder, and colon. Seventy-eight CC cases (4.5%) were diagnosed with at least 1 additional malignancy. In comparison with the baseline population risk, there was no statistically significant increased risk of any subsequent malignancy with a primary diagnosis of CC. Conclusions: This is the first large population-based analysis of second primary malignancies after type II endometrial cancers. Uterine papillary serous carcinoma is associated with increased risks of certain subsequent malignancies, and providers should be aware of these when following up patients with this diagnosis, especially those with stage I disease. In contrast, no such associations were found with CC in this cohort.
KW - Clear cell endometrial cancer
KW - Subsequent malignancies
KW - Type II endometrial cancer
KW - Uterine papillary serous carcinoma
UR - http://www.scopus.com/inward/record.url?scp=84880311758&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880311758&partnerID=8YFLogxK
U2 - 10.1097/IGC.0b013e3182959053
DO - 10.1097/IGC.0b013e3182959053
M3 - Article
C2 - 23748174
AN - SCOPUS:84880311758
SN - 1048-891X
VL - 23
SP - 1044
EP - 1049
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 6
ER -